Capricor Therapeutics, Inc. announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX?? exosome platform technology has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place in Baltimore, Maryland from May 7-11, 2024. The findings highlight a potential exosome-based approach for the treatment of arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease characterized by complete or partial lack of the enzyme arginase in the liver and red blood cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.68 USD | +2.34% | -5.18% | +16.16% |
May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.16% | 181M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting